title: Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
abstract: OBJECTIVE
  This pooled analysis was undertaken to assess the efficacy and toxicity of adjuvant cisplatin-based chemotherapy in elderly patients with non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  We used individual patient data from 4,584 patients enrolled onto five trials of cisplatin-based chemotherapy who form the basis for the Lung Adjuvant Cisplatin Analysis (LACE) pooled analysis. Patient and treatment characteristics, overall and event-free survival, cause-specific mortality, chemotherapy toxicity and delivery were compared among three age groups: 3,269 young (71%; < 65), 901 midcategory (20%; 65 to 69), and 414 elderly patients (9%; >or= 70). Log-rank tests stratified by trials were used with a test for trend to study the effect of chemotherapy on survival according to age.
  
  
  RESULTS
  The hazard ratio (HR) of death for the young patients was 0.86 (95% CI, 0.78 to 0.94), 1.01 for the midcategory (95% CI, 0.85 to 1.21), and 0.90 for elderly patients (95% CI, 0.70 to 1.16; test for trend: P = .29). The HR for event-free survival was 0.82 for young (95% CI, 0.75 to 0.90), 0.90 for the midcategory (95% CI, 0.76 to 1.06), and 0.87 for elderly patients (95% CI, 0.68 to 1.11; test for trend: P = .42). More elderly patients died from non-lung cancer-related causes (12% young, 19% midcategory, 22% elderly; P < .0001). No differences in severe toxicity rates were observed. Elderly patients received significantly lower first and total cisplatin doses, and fewer chemotherapy cycles (chi(2) P < .0001).
  
  
  CONCLUSIONS
  Adjuvant cisplatin-based chemotherapy should not be withheld from elderly patients with NSCLC purely on the basis of age.
authors.affiliation: Department of Medical Oncology, Princess Margaret Hospital, Toronto. martin.frueh@kssg.ch
authors.forename: Martin
authors.initials: M
authors.lastname: Früh
authors.forename: Estelle
authors.initials: E
authors.lastname: Rolland
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Pignon
authors.forename: Lesley
authors.initials: L
authors.lastname: Seymour
authors.forename: Keyue
authors.initials: K
authors.lastname: Ding
authors.forename: Hélène
authors.initials: H
authors.lastname: Tribodet
authors.forename: Timothy
authors.initials: T
authors.lastname: Winton
authors.forename: Thierry
authors.initials: T
authors.lastname: Le Chevalier
authors.forename: Giorgio V
authors.initials: GV
authors.lastname: Scagliotti
authors.forename: Jean Yves
authors.initials: JY
authors.lastname: Douillard
authors.forename: Stephen
authors.initials: S
authors.lastname: Spiro
authors.forename: Frances A
authors.initials: FA
authors.lastname: Shepherd
mesh_terms: D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin